Carbonic Anhydrases III and IV Autoantibodies in Rheumatoid Arthritis, Systemic Lupus Erythematosus, Diabetes, Hypertensive Renal Disease, and Heart Failure
Table 2
The disease indicators of subjects (mean (SD)).
RA
SLE
T1D
T1DN
T2D
T2DN
HTN
HT
RF (U/mL)
control
7.6 (5.2)
5.8 (3.5)
6.9 (4.3)
7.2 (4.3)
7.5 (3.4)
8.1 (3.9)
7.7 (3.1)
6.7 (4.1)
patients
108.4* (51.9)
63.8* (7.9)
11.4 (5.6)
12.3* (5.3)
9.1 (4.8)
10.5* (6.7)
8.2 (4.1)
7.5 (3.2)
positive
83.2%
50.3%
3.9%
5.1%
6.4%
5.8%
2.8%
2.1%
ASO (IU/mL)
control
133.1 (23.2)
118.5 (31.4)
115.8 (21.7)
113.6 (35.7)
129.5 (41.5)
123.4 (43.7)
141.3 (32.4)
135.4 (39.8)
patients
151.6* (45.5)
135.4* (42.3)
125.6 (33.9)
154.2* (36.8)
123.8 (41.6)
139.8 (37.9)
133.1 (45.8)
128.3 (21.5)
positive
7.8%
6.5%
6.3%
7.2%
4.1%
5.9%
3.8%
2.2%
Anti-CCP (U/mL)
control
2.6 (0.7)
3.1 (0.8)
ND
ND
ND
ND
ND
ND
patients
63.7 (33.5)
17.0 (5.9)
ND
ND
ND
ND
ND
ND
positive
61.2%
11.2%
ND
ND
ND
ND
ND
ND
ESR, (mm/h)
control
ND
ND
ND
ND
ND
ND
ND
ND
patients
41 (15)
37 (9)
18 (7)
17 (9)
15 (6)
19 (5)
11 (3)
11 (4)
elevated
79.2% †
65.1% †
5.5%
3.5%
1.7%
2.4%
1.3%
1.9%
hsCRP (mg/L)
control
1.8 (0.7)
2.1 (0.9)
2.3 (0.7)
1.8 (0.5)
2.4 (0.5)
3.2 (1.2)
2.9 (1.3)
2.8 (2.1)
patients
12.8* (5.7)
16.5* (8.2)
3.1 (1.2)
6.3* (0.8)
2.3 (0.8)
3.7 (1.5)
4.4 (1.5)
5.1 (1.9)
elevated
35.8%
42.5%
3.9%
4.8%
5.1%
5.5%
7.8%
6.7%
*There were significant differences between patients and control (P < 0.05). †There were significant differences between T1D, T1DN, T2D, T2DN, HTN, and HT groups. HTN: hypertensive nephropathy; HT: heart failure; ND: not determined.
